Reversible orofacial dyskinesia after ofloxacin treatment

Movement Disorders

Volumn 19, Issue 6, 2004, Pages 731-732

  De Bleecker, Jan L ^a   Vervaet, Veerle L ^a   De Sarro, Angela ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Fluoroquinolones; GABA; Ofloxacin; Orofacial dyskinesia

Indexed keywords

BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VENLAFAXINE;

ADULT; ARTICLE; CASE REPORT; CHOREOATHETOSIS; DEPRESSION; DISEASE ASSOCIATION; DRUG OVERDOSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GABAERGIC TRANSMISSION; HUMAN; INVOLUNTARY MOVEMENT; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; NEUROLOGIC EXAMINATION; OROFACIAL DYSKINESIA; PHANTOM PAIN; PRIORITY JOURNAL; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTI-INFECTIVE AGENTS; ANTIPARKINSON AGENTS; BIPERIDEN; DYSKINESIA, DRUG-INDUCED; HUMANS; MALE; RESPIRATORY TRACT INFECTIONS;

EID: 4444320677     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20053     Document Type: Article

References (7)

1. De Sarro A, De Sarro G. Adverse reactions to the fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem 2001;8:371-384.
2. Norrby SR. Side-effects of quinolones: comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10:378-383.
3. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999;28:352-364.
4. Thomas RJ., Reagan DR. Association of a Tourette-like syndrome with ofloxacin. Ann Pharmacother 1996;30:138-141.
5. Pastor P, Moitinho E, Elizalde I, Cirera I, Tolosa E. Reversible oro-facial dyskinesia in a patient receiving ciprofloxacin hydrochloride. J Neurol 1996;243:616-617.
6. Lee CH, Cheung RT, Chan TM. Ciprofloxacin-induced oral-facial dyskinesia in a patient with normal liver and renal function. Hosp Med 2000;61:142-143.
7. Tzallas PJ, Rynn KO. Extrapyramidal side-effects secondary to venlafaxine [abstract]. J Toxicol Clin Toxicol 1995;33:518.